<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914860</url>
  </required_header>
  <id_info>
    <org_study_id>Volunteers+AF patients</org_study_id>
    <nct_id>NCT02914860</nct_id>
  </id_info>
  <brief_title>Comparison of the Ganglionated Plexi Activity in Patients With Different Forms of Atrial Fibrillation Guided by SUMO Technology</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spectrum Dynamics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare DUA (discrete uptake accumulations) of mIBG activity
      in patients with different forms of atrial fibrillation and within a sub-group of healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>location of discrete uptake accumulations</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with paroxysmal atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pers AF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with persistent atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-s Pers AF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with long-standing persistent atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac CT</intervention_name>
    <description>Cardiac CT - contract enhanced cardiac CT according to standard protocol
D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)
Merge CT and D-SPECT image data to generate SUMO map.</description>
    <arm_group_label>Volunteers</arm_group_label>
    <arm_group_label>PAF</arm_group_label>
    <arm_group_label>Pers AF</arm_group_label>
    <arm_group_label>L-s Pers AF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation Procedure</intervention_name>
    <description>CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.
High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).
RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)
Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA
Control HFS
At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.
Exit and entrance block confirmation
Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia.</description>
    <arm_group_label>PAF</arm_group_label>
    <arm_group_label>Pers AF</arm_group_label>
    <arm_group_label>L-s Pers AF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>D-SPECT</intervention_name>
    <arm_group_label>Volunteers</arm_group_label>
    <arm_group_label>PAF</arm_group_label>
    <arm_group_label>Pers AF</arm_group_label>
    <arm_group_label>L-s Pers AF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients, age ≥ 18 and ≤ 80 years.

          2. Male or female, age ≥ 50 years in the healthy volunteers group

          3. No heart pathology (for volunteers)

          4. PAF, Pers AF and L-s Pers AF (ECG documented).

          5. LVEF ≥ 50%

          6. Able to provide written informed consent

          7. Able to comply with the requirements of the study

        Exclusion Criteria:

          1. Previous AF ablation therapy

          2. Clinical evidence of active coronary ischemia, significant valvular heart disease, or
             hemodynamically significant congenital cardiac abnormality

          3. Recent (3 months) myocardial infarction (MI), stroke or transient ischemic attack
             (except if the patient had a DES implanted stent post-MI it would be one year)

          4. Contra-indication to Iodine-123 Meta-iodobenzylguanidine (123I-mIBG), iodine,
             isoproterenol

          5. Use of medication for non-cardiac medical conditions that is known to interfere with
             123I-mIBG uptake and cannot be safely withheld for at least 24 hours prior to the
             D-SPECT study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexander Romanov</last_name>
    <email>abromanov@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Research Institute of CIrculation Pathology Novosibirsk, Russian Federation</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Pokushalov, MD, PhD</last_name>
      <phone>+79139254858</phone>
      <email>E.Pokushalov@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Evgeny Pokushalov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Romanov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Losik</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

